ongestive heart failure (CHF) is a highly prevalent disorder that is associated with repeated hospitalization, high morbidity and mortality. Because ventricular arrhythmia is one of the major causes of poor prognosis in CHF patients, 1 it is associated with excess mortality.
Sleep-related periodic breathing with recurrent episodes of apnea is known to occur in patients with CHF. [2] [3] [4] [5] This breathing disorder may be associated with arterial oxyhemoglobin desaturation and excessive arousals, resulting in sympathetic activation and arrhythmias. 6, 7 Because sleep-disordered breathing is also observed in patients with idiopathic cardiomyopathy, 8 the pathophysiological consequences of sleep apnea may further contribute to the mortality of CHF patients with ventricular arrhythmias. Although home oxygen therapy 9 and bi-level positive airway pressure treatment 10, 11 improve the clinical condition of sleep apnea syndrome (SAS) in CHF patients, few studies of SAS in CHF with ventricular arrhythmias have been reported and detailed findings and laboratory examinations for arrhythmia in SAS and CHF are needed.
In this study, we studied patients with stable CHF to determine (1) the clinical characteristics and the prevalence of premature ventricular contraction (PVC) in patients with CHF and SAS, (2) the clinical features of the CHF with SAS patients with or without frequent PVCs, (3) the effects of nasal oxygen therapy for prevention of PVCs in patients with CHF and SAS, and (4) the clinical features of patients with CHF and SAS who are effectively treated with oxygen.
Methods

Subjects
We recruited 50 patients with CHF admitted to the Department of Cardiovascular Medicine of the Tokyo Medical and Dental University Hospital. Patients <80 years of age were eligible if they met the following criteria: at least 1 episode of cardiac decompensation; and stable condition while receiving cardiac medication. Exclusion criteria were: myocardial infarction within 1 year of study entry; significant obstructive lung disease; unstable angina; unstable heart failure; acute pulmonary edema; congenital heart disease; severe renal and liver disorders; untreated hypothyroidism; and use of morphine derivatives, benzodiazepine, or theophylline. This study was approved by the ethics committee of Tokyo Medical and Dental University. Written informed consent was given by all participants. Medication (eg, diuretics, angiotensin-converting enzyme inhibitors (ACE), angiotensin II receptor antagonists (ARBs), -blockers, digoxin, isosorbide dinitrates) dosages had been adjusted on the basis of the hemodynamic and clinical status of each patient and had not been changed within the previous 2 weeks. The etiologies of heart failure were At the time of the recruitment, no information was sought about symptoms or risk factors for SAS and arrhythmia. The patients were admitted to the hospital for at least 2 consecutive nights for this study. Caffeinated products were avoided during hospitalization. On the first day, a detailed history was obtained and physical examination was performed. The following tests were also carried out: complete blood count, serum electrolytes, blood urea nitrogen, serum creatinine, brain natriuretic peptide (BNP), echocardiography (UCG), and chest X-ray (X-p).
Sleep Study
Holter electrocardiogram (ECG) and respiratory monitoring were performed using the Morpheus C system (Teijin Pharma Co, Tokyo, Japan) consisting of a flow sensor for nasal and oral breath flows, a 3-channel electrocardiograph, and 1 stress-sensitive belt each for the thorax and the abdomen. 12, 13 For each subject, the overnight sleep study was recorded between 21.30 h and 05.30 h. On the first night, the respiratory and Holter monitoring was performed without nasal oxygen treatment; the same monitoring with nasal oxygen therapy (3 L/min) was performed on the second night. The data were stored on a computer which automatically calculated the apnea hypopnea index (AHI), the apnea index (AI), and the oxygen desaturation index (ODI). The ODI was defined as the number of events per hour of sleep in which oxygen saturation decreased by 4% or more. Apnea was diagnosed in patients in whom respiratory flow was reduced to <20% of normal for at least 10 s. The AI was defined as the number of episodes of obstructive apnea per hour of sleep. The AHI was defined as the number of episodes of apnea and hypopnea per hour of sleep; patients who had a score of 5 or more for AHI were diagnosed as having SAS. 14, 15 Holter Monitoring
All patients and control subjects underwent Holter recording with 3-channel real-time recorders. For each patient, the total number of PVCs, ventricular couplets, and episodes of ventricular tachycardia (defined as ≥3 consecutive PVC with a rate ≥100 beats/min) were recorded. Heart rate variability (HRV) was assessed, both in time and frequency domains, on the Holter recordings after full revision of the ECG and editing of beats where indicated. During the analysis, only normal beats were measured, and all artifacts were eliminated. Time-domain HRV variables included the mean of all R-R intervals for the entire recording; the standard deviation of all R-R intervals (SDNN) was measured. In the frequency domain, HRV was assessed in the range of frequencies of 0-0.4 Hz by a fast-Fourier transform spectral analysis algorithm, with a spectral resolution of 0.0005 Hz, with the use of the aforementioned Brentwood software. The amplitude of the following frequency-domain HRV variables was obtained: low-frequency (LF, 0.04-0.15 Hz), high-frequency (HF, 0.15-0.40 Hz), and the lowfrequency/high-frequency (LF/HF) ratio. The amplitude values of LF, HF, and LF/HF ratio were also obtained for each hour of the day. [12] [13] [14] [15] Other Studies Left ventricular ejection fraction (LVEF) was calculated from the echocardiogram by standard techniques. Chest X-p and arterial blood samples were obtained according to strict criteria as previously reported. 16, 17 
Statistical Analysis
We used the Wilcoxon rank-sum test to assess significant differences between the groups, because the data were not normally distributed. A value of p<0.05 was considered significant. Values are reported as mean ± SD.
Results
Frequent PVC Group
In this study, 37 of 50 patients were diagnosed with SAS and CHF, and we analyzed arrhythmia in all 37 patients. According to our defined thresholds, there were 15 patients (group 1, frequent PVCs) who had frequent PVCs (>30 PVCs/h) and the mean (± SD) number of total PVCs was 1,970±721 per 8 h. The remaining 22 patients (group 2, few PVCs) had fewer PVCs (<30 PVCs/h) and the mean was 9.8±2.9 per 8 h. Between the 2 groups, average SpO2 levels were statistically different: group 1 showed a lower level (93±1.3%) than group 2 (96±0.5%, p<0.05 vs group 1). All other factors, including background diseases and -blocker treatment, were statistically comparable between the 2 groups ( Table 1) .
Effect of Oxygen Treatment on Number of PVCs
Because the only significant factor was the average SpO2 level, we tried to clarify the effects of oxygen therapy (3 L/min nasal O2 supply) on the number of PVCs in this group. Although average heart rate, SpO2 level and AHI improved with the oxygen treatment, PVC numbers before (1,970±721) and after (1,559±420) treatment were not statistically different. SDNN was also comparable before and after the treatment ( Table 2) .
Mechanism of Effect of Oxygen Therapy on PVCs in CHF
The 15 patients in group 1 (frequent PVCs) were further subdivided into 2 groups: "PVC declined" (n=6) group had patients who had frequent PVCs and oxygen treatment suppressed (>50% decline) the number of PVC, and "PVC not affected" (n=9) group which was those who had frequent PVCs and oxygen treatment did not affect (<50% decline) the number of PVC.
A representative case group 1 (Fig 1) was a 79-year-old male who had dilated cardiomyopathy and was suffering from leg edema and dyspnea. His height was 166 cm and weight was 83 kg; blood pressure was 130/80 mmHg and pulse was 72 beats/min regular. His blood examination showed anemia (hemoglobin (Hb) 9.1 mg/dl), renal dysfunction (creatinine 1.56 mg/dl) and a high BNP level (953.4 pg/ml). The ECG showed frequent PVCs with sinus rhythm. Chest X-p showed enlarged cardiothoracic ratio (62%), and pulmonary edema with enlarged pulmonary arteries. Echocardiogram showed good ejection fraction (EF) (62%), and enlarged left atrial diameter (56 mm). Frequency of PVCs (8,770 /8 h without oxygen vs 4,162 /8 h with oxygen) and sleep apnea (AHI: 71.9 without oxygen vs 13.7 with oxygen) with desaturation (average SpO2: 90% without oxygen vs 98% with oxygen) were both significantly improved by the oxygen therapy.
A representative case from group 2 (Fig 2) was a 73-year-old male who had a valve disease and was suffering from dyspnea. His height was 163 cm and weight was 66 kg; blood pressure was 130/80 mmHg and pulse was 72 beats/min regular. His blood examination showed mild anemia (Hb 12.6 mg/dl), renal dysfunction (creatinine 0.88 mg/dl) and BNP elevation (90.6 pg/ml). The ECG showed frequent PVCs with sinus rhythm. Chest X-p showed normal cardiothoracic ratio (51%), and enlarged pulmonary arteries. Echocardiogram showed borderline EF (53%), enlarged left atrial diameter (51 mm) and severe tricuspid regurgitation. Although sleep apnea (AHI: 22.2 without oxygen vs 14.5 with oxygen) with desaturation (average SpO2: 92% without oxygen vs 96% with oxygen) was improved by the oxygen therapy, the number of PVCs was not suppressed (4,244/8 h without oxygen vs 4,599/8 h with oxygen) by the treatment.
Characteristics of Group 1
Statistically, higher serum BNP levels (780±233 vs 236± 96, p<0.05), greater LVEF in UCG (49.0±8.1 vs 32.7±5.0, p<0.05), more PVCs before the oxygen treatment (3,341± 1,576 vs 1,056±471, p<0.05), higher AHI (29±1.3 vs 15±4, p<0.05), and higher SDNN (215±121 vs 84±13, p<0.05) were observed in group 1. All other factors, including New York Heart Association grading, background diseases, -blocker treatment, and ODI, were statistically comparable between the 2 groups (Table 3) .
Discussion
The pathophysiology of ventricular arrhythmia in CHF patients with SAS is complex and not completely understood. The individual apneic events have a considerable hemodynamic impact that is mediated by a complicated sequence of pathophysiologic events, such as vascular endothelial dysfunction 18 and altered central chemosensitivity. 19 Several important regulatory mechanisms in cardiovascular homeostasis seem to be influence the number of PVCs in CHF. In this study, patients with frequent PVCs with CHF and SAS showed less average SpO2 levels than patients with less frequent PVCs. Oxygen therapy was used to suppress the number of PVCs in the CHF and SAS patients, but we could not reveal any effects statistically because there was a large standard deviation among the patients. Therefore, we tried to reveal which factors are critical in the beneficial effect of oxygen therapy suppressing PVCs.
In the present study, patients with CHF and SAS who had frequent PVCs were further subdivided into 2 groups: the oxygen effective group and oxygen non-effective group. It has been shown that the frequency and severity of arrhythmia can increase in SAS patients. [20] [21] [22] We confirmed that oxygen treatment for prevention of PVCs is effective in patients with higher BNP levels, greater LVEF, and higher SDNN, which suggests that the oxygen therapy can affect both the physiological disorder and the impaired cardiac autonomic function that produce the PVCs.
First, the impairment of cardiac autonomic function in CHF patients with SAS can be a trigger for ventricular arrhythmia and nasal oxygen therapy may suppress the ventricular arrhythmia through the improvement of cardiac autonomic function. An altered autonomic balance has been suggested as a possible pathogenetic factor, and autonomic dysfunction is implicated in the subsequent development of cardiovascular diseases in CHF patients with SAS. [23] [24] [25] [26] [27] [28] [29] Time-domain and spectral HRV analysis are powerful tools for investigating arrhythmia in CHF patients with SAS. Spectral analysis of the HRV is a commonly used method for evaluating the autonomic modulation of the heart rate and arrhythmia. It gives selective information on parasympathetic and sympathetic function and moreover, because the method is noninvasive, it is appropriate for clinical studies. Spectral analysis is reproducible and has a better sensitivity and specificity than do the previously used timedomain methods in short-term studies of cardiovascular reflex. 30, 31 In another variation from previous studies, our recording system using Morpheus C provided information for both spectral and time-domain analyses. In this study, we could not clarify the difference of SDNN before and after the oxygen therapy because the time protocol was too short to detect the change. However, SDNN may change after a longer observation, so further study of the effects on SDNN using long-term observation is needed. From our results, nasal oxygen therapy may be effective for suppressing PVCs in CHF patients with SAS when the patient has impaired autonomic function. Second, we also revealed that the oxygen-effective group had higher BNP levels and greater LVEF than the noneffective group. Recently, it was reported that plasma BNP level and cardiac autonomic function are closely related to prognosis in patients with heart failure. Plasma BNP levels are also known to be a strong predictor for mortality in heart failure patients and the BNP levels are statistically related to cardiac sympathetic nerve innervation. 32 Another study indicated that increased plasma BNP levels were related to cardiac reflex parasympathetic dysfunction in type 2 diabetic patients. 33 In the present study, higher BNP levels and LVEF could be the result of insufficient treatment with conservative therapies, including -blockers and other medicines. It is well known that conservative treatment of CHF using -blockers, ACE inhibitors, and ARBs improves the prognosis of CHF patients. However, these drugs are not able to be used in some cases because of hypotension, bradycardia, and/or systemic adverse effects, which was the situation in the present study, and oxygen therapy should be used in CHF patients with such conditions as an alternative treatment for CHF. At present, the detailed relationship between oxygen treatment and BNP levels is not understood, but patients with high BNP may be good candidates for oxygen treatment for the suppression of PVCs.
We conclude that (1) desaturation and cardiac autonomic activity is altered in some CHF patients, (2) this alteration may be one of the causes of ventricular arrhythmia, and (3) oxygen therapy may be effective for suppression of PVCs when the CHF patient has desaturation, high BNP and/or impaired autonomic function.
